Table 3.
Prevalence of risk factors and arterial and liver diseases among carriers and noncarriers of ANGPTL3 S17X mutation
| Variables | Carriers (n = 63) |
Noncarriers (n = 341) | |
|---|---|---|---|
| Homozygous (n = 8) | Heterozygous (n = 55) | ||
| Age (yr) | 64.8 ± 14.2 | 49.8 ± 20.4 | 52.9 ± 20.0 |
| Sex (M/F) | 4/4 | 24/31 | 161/180 |
| BMI (kg/m2) | 29.4 ± 6.2 | 28.7 ± 5.1 | 27.5 ± 4.9 |
| Menopause, n (%) | 3 (37.5) | 16 (29.1) | 95 (27.9) |
| Fasting blood glucose (mmol/liter) | 4.6 ± 0.5a,b | 5.5 ± 1.5 | 5.5 ± 1.3 |
| Systolic blood pressure (mm Hg) | 135.5 ± 30.5 | 129.9 ± 20.9 | 130.6 ± 19.7 |
| Diastolic blood pressure (mm Hg) | 81.2 ± 9.8 | 81.3 ± 10.3 | 81.1 ± 10.0 |
| Smokers, n (%) | 2 (25.0) | 12 (21.8) | 70 (20.5) |
| Alcohol consumption, n (%) | |||
| Moderate drinkers | 6 (75.0) | 37 (67.3) | 213 (62.5) |
| Abstainers | 2 (25.0) | 18 (32.7) | 128 (37.5) |
| Hypertension, n (%) | 2 (25.0) | 15 (27.3) | 85 (24.9) |
| Diabetes, n (%) | 0 | 4 (7.3) | 34 (10.0) |
| Coronary heart disease, n (%) | 0 | 5 (9.1) | 16 (4.7) |
| Cerebro vascular disease, n (%) | 0 | 4 (7.3) | 24 (7.0) |
| Liver disease, n (%) | |||
| Hypertransaminasemia | 2 (25.0) | 7 (12.7) | 59 (17.4) |
| Cholelithiasis | 0 | 0 | 12 (3.5)c |
| Chronic hepathitis | 0 | 0 | 3 (0.9) |
| Cirrhosis | 0 | 1 (1.8) | 0 |
Hypertransaminasemia was defined as plasma concentration of aspartate aminotransferase and/or alanine aminotransferase greater than 40 U/liter. The diagnosis of type 2 diabetes mellitus was based on history of treatment with hypoglycemic agents and/or fasting blood glucose greater than 126 mg/dl and that of hypertension on the presence of elevated systolic (>140 mm Hg) and/or diastolic (>90 mm Hg) blood pressure and/or the current use of antihypertensive drugs. M, Male; F, female.
P < 0.01 for comparison between homozygous carriers vs. noncarriers.
P < 0.05 for comparison between homozygous vs. heterozygous carriers.
P < 0.05 for comparison between homozygous carriers vs. noncarriers.